Novartis is laying off 139 employees in East Hanover, NJ, primarily affecting commercial field sales teams working on Xolair (allergy/asthma) and Tafinlar-Mekinist (cancer) treatments. The cuts, ...

FDA accepts Satsuma Pharmaceuticals' NDA resubmission for STS101 migraine drug. Hovione expands facilities in Ireland and New Jersey. Adragos Pharma acquires Baccinex. Gelteq plans gel solution ...

Outlook Therapeutics' ONS-5010 (bevacizumab) failed to meet its primary endpoint in a Phase 3 trial against Roche's Lucentis ...

Recursion Pharmaceuticals laid off under 20% of staff following merger with Exscientia. Oxford Nanopore partners with UK Biobank for epigenetic dataset project. Portage Biotech continues strategic ...

Bristol Myers Squibb is the latest pharma company to sue the federal government over its rejection of a proposed new model ...

Kronos Bio announces 83% workforce reduction and CEO Norbert Bischofberger's departure, with CFO Deborah Knobelman taking ...

Acadia Pharmaceuticals will pay Saniona $28 million upfront and up to $582 million in milestone payments for SAN711, an ...

President-elect Trump selected Jay Bhattacharya, Stanford professor and Covid-19 lockdown critic, to lead NIH, and Jim ...

Axsome Therapeutics’ narcolepsy drug AXS-12 hit the primary endpoint in its Phase 3 ENCORE trial, showing a statistically ...

Sarepta Therapeutics and Arrowhead Pharmaceuticals teamed up on an siRNA partnership that has one of the biggest promises of ...

Alladapt Immunotherapeutics, a well-financed biotech working in the food allergy field, shut down following talks with the ...

FDA extends review of Soleno Therapeutics' diazoxide choline extended-release tablets for Prader-Willi syndrome by three ...